Corcept Therapeutics Inc
CORTHealthcare|Biotechnology|USA
$91.88
-1.37 (-1.47%)
DCF (FCF)
$25.10
Tangible Book
$5.94
Graham Number
$6.84
Earnings Power
$19.15
Clinical Trials (79)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05257408 Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | Ovarian Neoplasm, Fallopian Tube Neoplasms | P3 | Active | 381 | RCT, Open-label | Nab-paclitaxel 80 mg/m^2, Relacorilant 150 mg once daily (QD), Nab-paclitaxel 100 mg/m^2 |
| NCT06099769 A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | Metastatic Breast Cancer | P2 | Recruiting | 201 | RCT, Open-label | Enzalutamide, Mifepristone, TPC |
| NCT07276373 Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies | Neoplasms | P1P2 | Recruiting | 50 | Open-label | Nenocorilant 200 mg, Nenocorilant 300 mg, Nenocorilant 400 mg, Nivolumab |
| NCT06689254 REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonism | Treatment-resistant PTSD | P2 | Recruiting | 60 | RCT, Double-blind | Mifepristone 1200 mg daily, Placebo |
| NCT06906341 Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | Ovarian Cancer, Fallopian Tube Cancer | P2 | Recruiting | 270 | Open-label | Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg |
| NCT07259317 Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | Adenocarcinoma, Carcinoma, Pancreatic Ductal | P2 | Recruiting | 80 | Open-label | Relacorilant, Nab-paclitaxel, Gemcitabine |
| NCT05407324 Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | P2 | Recruiting | 279 | RCT, Double-blind | Dazucorilant 300 mg, Dazucorilant 150 mg, Dazucorilant |
| NCT06108219 A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) | Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH) | P2 | Active | 175 | RCT, Double-blind | Miricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B), Placebo (Cohort B) |
| NCT03604198 Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | Cushing Syndrome | P2 | Active | 125 | Open-label | relacorilant |
| NCT07553663 Evaluating the Pharmacokinetics and Safety of Miricorilant | Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis | P1 | Recruiting | 15 | Open-label | Miricorilant |
| NCT06947304 Evaluation of Miricorilant on Liver Fat in Patients With MASLD | Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) | P1 | Recruiting | 8 | Open-label | Miricorilant |
| NCT05772169 Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST) | Hypercortisolism, Diabetes Mellitus, Type 2 | P4 | Completed | 1,113 | RCT, Double-blind | Mifepristone 300 MG [Korlym], Placebo for mifepristone |
| NCT00128505 An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression | Major Depressive Disorder, Psychotic Disorders | P3 | Completed | 104 | Open-label | Mifepristone |
| NCT00146523 An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression | Major Depressive Disorder | P3 | Completed | 247 | RCT, Double-blind | Mifepristone, placebo |
| NCT00208156 A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression | Depressive Disorder, Major | P3 | Completed | 87 | Open-label | Mifepristone |
| NCT04308590 A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas | Hypercortisolism | P3 | Completed | 137 | RCT, Double-blind | Relacorilant |
| NCT00637494 A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features | Psychotic Depression, Severe Major Depression With Psychotic Features | P3 | Terminated | 292 | RCT, Double-blind | mifepristone, placebo |
| NCT01925092 Mifepristone in Children With Refractory Cushing's Disease | Cushing's Disease | P3 | Withdrawn | — | Open-label | mifepristone |
| NCT04329949 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Ductal Adenocarcinoma | P3 | Terminated | 43 | Open-label | Relacorilant, 100 mg and 25 mg, Nab-paclitaxel |
| NCT00130676 A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression | Major Depressive Disorder, Psychotic Disorders | P3 | Completed | 257 | RCT, Double-blind | Mifepristone, matching placebo |
| NCT00128479 A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression | Major Depressive Disorder, Psychotic Disorders | P3 | Completed | 443 | RCT, Double-blind | mifepristone, mifepristone matched placebo, mifepristone 600 mg, mifepristone 1200 mg |
| NCT01371565 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome | Cushing's Disease, Cushing's Syndrome | P3 | Completed | 4 | Open-label | Mifepristone |
| NCT00936741 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome | Cushing's Syndrome | P3 | Completed | 30 | Open-label | mifepristone |
| NCT00569582 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome | Cushing's Syndrome | P3 | Completed | 50 | Open-label | mifepristone |
| NCT03697109 A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome | Cushing Syndrome | P3 | Completed | 152 | RCT, Double-blind | Relacorilant |
| NCT04588688 Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency | Central Adrenal Insufficiency, Mifepristone | P2 | Terminated | 3 | Open-label | Mifepristone |
| NCT00105105 Mifepristone as Adjunctive Therapy in Alzheimer's Disease | Alzheimer's Disease | P2 | Terminated | 160 | RCT, Double-blind | Mifepristone |
| NCT04524403 A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II) | Antipsychotic-induced Weight Gain (AIWG) | P2 | Completed | 150 | RCT, Double-blind | Miricorlilant, Miricorlilant, Placebo |
| NCT03437941 Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer | P1P2 | Terminated | 39 | RCT, Double-blind | Exicorilant, Enzalutamide, Placebo |
| NCT02762981 Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors | Solid Tumors | P1P2 | Completed | 85 | Open-label | Relacorilant with nab-paclitaxel |
| NCT05217758 RESET-medication Glucocorticoid Receptor (GR) Blockade As Disease Modifying Treatment for Depression with Childhood Trauma | Major Depressive Disorder, Childhood Trauma | P2 | Completed | 158 | RCT, Double-blind | Mifepristone, Placebo |
| NCT00455442 A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain | Weight-Gain Prevention | P2 | Completed | 57 | RCT, Double-blind | Mifepristone |
| NCT03818256 A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications | Antipsychotic-induced Weight Gain (AIWG) | P2 | Completed | 71 | RCT, Double-blind | Miricorilant, Placebo |
| NCT03823703 Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis (NASH) | P2 | Terminated | 12 | RCT, Double-blind | Miricorilant, Placebo |
| NCT02642939 Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | P2 | Terminated | 3 | Open-label | Mifepristone |
| NCT02804750 Study to Evaluate CORT125134 in Participants With Cushing's Syndrome | Cushing's Syndrome | P2 | Completed | 35 | Open-label | CORT125134 |
| NCT03776812 Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma | P2 | Completed | 178 | RCT, Open-label | Relacorilant, Nab-paclitaxel |
| NCT06928779 Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant | Hepatic Impairment | P1 | Completed | 19 | Open-label | Dazucorilant |
| NCT03877562 The Effect of CORT118335 on Olanzapine-Induced Weight Gain | Antipsychotic-induced Weight Gain | P1 | Completed | 96 | RCT, Double-blind | Olanzapine, CORT118335, Placebo |
| NCT06094790 A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects | Healthy | P1 | Completed | 32 | RCT, Open-label | CORT125134 150 mg, CORT125134 250 mg, CORT125134 dose to be determined |
| NCT06495944 Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants | Healthy Adults | P1 | Completed | 21 | Open-label | Dazucorilant, Itraconazole |
| NCT04990310 Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants | Healthy | P1 | Completed | 6 | Open-label | [14C]-CORT113176 |
| NCT00698022 A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers | Healthy | P1 | Completed | 76 | RCT, Double-blind | Risperidone, Mifepristone, Risperidone-matched placebo, Mifepristone-matched placebo |
| NCT03067376 A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body | Healthy | P1 | Completed | 9 | Open-label | [14C]-CORT125134 |
| NCT00752843 A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers | Healthy Subjects | P1 | Completed | 20 | Open-label | mifepristone + fluvastatin |
| NCT04249323 Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants | Healthy Adults | P1 | Completed | 110 | RCT, Double-blind | CORT113176 Lipid Capsule Formulation, Placebo matching CORT113176 Lipid Capsule Formulation, Prednisone |
| NCT03508635 CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) | Healthy | P1 | Completed | 130 | RCT, Double-blind | CORT125134, Matching Placebo of CORT125134, Mifepristone, Prednisone, Glucose |
| NCT05117489 A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis (NASH) | P1 | Completed | 70 | Open-label | Miricorilant 150 mg, Miricorilant 100 mg, Miricorilant 50 mg, Miricorilant 10 mg |
| NCT03512548 Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites | Healthy | P1 | Completed | 52 | Open-label | Relacorilant 350mg, Itraconazole, Relacorilant 300mg |
| NCT03674814 Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer | Prostate Cancer | P1 | Completed | 42 | Open-label | Enzalutamide, Relacorilant |
| NCT05347979 Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants | Cushing Syndrome, Neoplasms | P1 | Completed | 30 | Open-label | Dabigatran Etexilate, Relacorilant |
| NCT06094738 A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects | Healthy | P1 | Completed | 30 | RCT, Open-label | Relacorilant under fasted conditions, Relacorilant after a high-fat meal, Relacorilant after a low-fat meal |
| NCT05553470 Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant | Non-alcoholic Steatohepatitis (NASH) | P1 | Completed | 19 | Open-label | Miricorilant |
| NCT06094725 A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant | Hepatic Impairment | P1 | Completed | 30 | Open-label | Relacorilant |
| NCT05003713 Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants | Healthy | P1 | Completed | 82 | RCT, Double-blind | CORT125236, Placebo matching CORT125236, Prednisone |
| NCT07240116 Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects | Healthy | P1 | Completed | 18 | RCT, Open-label | Miricorilant Treatment A, Miricorilant Treatment B, Miricorilant Treatment C, Miricorilant Treatment D |
| NCT05712265 Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant | Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH) | P1 | Completed | 26 | Open-label | Miricorilant, Fluvoxamine |
| NCT04672512 Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants | Healthy | P1 | Completed | 115 | RCT, Double-blind | CORT125329 lipid capsule formulation, Placebo, Prednisone |
| NCT03442621 Relacorilant Food Effect Study in Healthy Subjects | Healthy, Food-drug Interaction | P1 | Completed | 30 | RCT, Open-label | Relacorilant Fasted, Relacorilant with a high fat breakfast, Relacorilant with a moderate breakfast |
| NCT03258372 Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites | Healthy | P1 | Completed | 48 | Open-label | Mifepristone |
| NCT03540836 A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants | Healthy | P1 | Completed | 30 | RCT, Open-label | Relacorilant (3x100 mg softgel capsules), Relacorilant (3x100 mg hard-shell capsules), Relacorilant (6x50mg hard-shell capsules) |
| NCT03315338 First-in-human Study in Healthy Subjects | Healthy | P1 | Completed | 143 | RCT, Double-blind | CORT118335, 25 mg, Prednisone Oral Tablet, Glucose, Placebo oral suspension, CORT118335, 75mg, CORT118335, 225mg, CORT118335, 675mg, CORT118335, 600mg, CORT118335, 630mg, CORT118335, 375mg, CORT118335, 100mg, CORT118335, 300mg, CORT118335, 900mg, CORT118335, 150mg, CORT118335, 1500mg, Placebo oral capsule, CORT118335, dose to be determined |
| NCT02014337 Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Breast Cancer, Ovarian Epithelial Cancer Recurrent | P1 | Completed | 37 | Open-label | Mifepristone and Eribulin in combination |
| NCT03335956 CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) | Healthy | P1 | Completed | 48 | RCT, Double-blind | CORT125281, 40mg, fasted, Prednisone 25mg, fasted, Placebo oral capsule, fasted, Pioglitazone 15mg Tablet, Placebo oral capsule, fed, Prednisone 25mg, fed, CORT125281, 120mg, fasted, CORT125281, 360mg, fasted, CORT125281, 720mg, fasted, CORT125281, 360mg, fed, CORT125281, 360mg, CORT125281, 120mg, CORT125281, 180mg, CORT125281, 240mg, CORT125281, 360mg, Placebo oral capsule, Placebo oral capsule, Placebo oral capsule |
| NCT04994743 Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants | Healthy Adults | P1 | Completed | 16 | RCT, Double-blind | CORT113176, Placebo matching CORT113176 |
| NCT06094712 A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects | Healthy | P1 | Completed | 8 | Open-label | CORT125134 |
| NCT03457597 Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s | Healthy | P1 | Completed | 27 | Open-label | Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride, Tolbutamide, Omeprazole, Relacorilant |
| NCT03877952 Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants | Healthy | P1 | Completed | 6 | Open-label | 14C-CORT125281 |
| NCT04672499 Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants | Healthy | P1 | Completed | 36 | RCT, Double-blind | Miricorilant 300 mg tablets, Miricorilant 150 mg tablets, Placebo 150 mg tablets |
| NCT04373265 Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) | Adrenocortical Carcinoma | P1 | Completed | 15 | Open-label | Relacorilant, Pembrolizumab |
| NCT04795479 T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers | Healthy | P1 | Completed | 36 | RCT, Double-blind | Relacorilant, Placebo to relacorilant, Moxifloxacin |
| NCT03878264 Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants | Healthy | P1 | Completed | 12 | Open-label | CORT118335 Oral, 14C-CORT118335 intravenous, 14C-CORT118335 oral |
| NCT03259542 Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor | Drug Interaction Potentiation, Healthy | P1 | Completed | 33 | Open-label | Mifepristone 300 MG, Itraconazole 100 MG |
| NCT05320146 A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis (NASH) | Completed | 22 | — | — | |
| NCT00796783 A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia | Cushing's Syndrome | Terminated | 2 | — | Cushing's syndrome confirmation | |
| NCT02663609 Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome | Cushing's Syndrome | Completed | 24 | — | — | |
| NCT02922257 Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery | Cushing's Syndrome | Completed | 26 | — | — | |
| NCT06829537 Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM) | Resistant Hypertension, Hypercortisolism | Completed | 1,143 | — | — | |
| NCT03379363 Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome | Hypercortisolism, Cushing Syndrome | Terminated | 2 | — | — |